|
1
|
Neckel N, Lissat A, von Stackelberg A, Thieme N, Doueiri MS, Spors B, Beck-Broichsitter B, Heiland M, Raguse JD. Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature. Ther Adv Med Oncol 2019; 11:1758835919878013. [PMID: 31666812 PMCID: PMC6801882 DOI: 10.1177/1758835919878013] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2019] [Accepted: 08/30/2019] [Indexed: 12/17/2022] Open
Abstract
Langerhans cell histiocytosis (LCH) is a diagnostic and therapeutic challenge. We
report on a rare case of its primary oral manifestation that was treated
successfully with the BRAF-specific agent, vemurafenib, after insufficient
standard LCH treatment. This case underlines the importance of proper diagnosis
and the evaluation of targeted therapy as a valuable tool in LCH treatment.
Furthermore, the close collaboration of surgeons, oncologists, and dentists is
mandatory to ensure adequate treatment, restore the stomatognathic system in
debilitating post-treatment situations, improve quality of life, and ensure
effective disease control in infants and young patients.
Collapse
Affiliation(s)
- Norbert Neckel
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Oral and Maxillofacial Surgery, Augustenburger Platz 1, 13351 Berlin 13353, Germany
| | - Andrej Lissat
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatrics, Division of Oncology and Haematology, Berlin, Germany
| | - Arendt von Stackelberg
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatrics, Division of Oncology and Haematology, Berlin, Germany
| | - Nadine Thieme
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Radiology, Berlin, Germany
| | - Mohemed-Salim Doueiri
- Charité - Universitätsmedizin Berlin, Centre for Dental and Craniofacial Sciences, Department of Orthodontics, Dentofacial Orthopaedics and Paedodontics, Berlin, Germany
| | - Birgit Spors
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Radiology, Berlin, Germany
| | - Benedicta Beck-Broichsitter
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Oral and Maxillofacial Surgery, Berlin, Germany
| | - Max Heiland
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Oral and Maxillofacial Surgery, Berlin, Germany
| | - Jan-Dirk Raguse
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Oral and Maxillofacial Surgery, Berlin, Germany
| |
Collapse
|